Neurology® Podcast

1) Midlife systemic inflammatory markers are associated with late-life brain volume: The ARIC study2) What’s Trending: Neurology paper on breast feeding, ovulatory years, and risk of multiple sclerosisThis podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the November 28, 2017 issue of Neurology In the first segment, Dr. Jeff Burns talks with Dr. Keenan Walker about his paper on the association between systemic inflammation and brain volume over time. For our What’s Trending segment, Dr. Stacey Clardy focuses her interview with Dr. Annette Langer-Gould about her recent Neurology article on breast feeding, ovulatory years, and risk of multiple sclerosis.DISCLOSURES: Dr. Burns has served on the DSMB for NIH-funded trials (non-profit entities); serves on the editorial board for Journal of Alzheimer's Disease; has consulted for Grifols, USA; has served on Eli Lilly Amyvid Speaker's Bureau; and has received research support from Eli Lilly, Avid Radiopharmaceuticals, Toyama Chemical Company, Merck, Biogen, AbbVie, Novartis, vTv Therapeutics, Janssen, and NIH (R01AG058557, R01AG053312, R01AG034614, R01AG03367, R01AG043962, P30AG035982, U10NS077356, UL1TR000001)Dr. Walker has received research support from the National Institute of Aging (AG027668, postdoc fellow, 2016-17).Dr. Clardy has received research support from Western Institute for Biomedical Research (WIBR).Dr. Langer-Gould has received research support from Biogen, Roche, NIH, PCORI, and the National Multiple Sclerosis Society.

Show description/summary:1) Multiparametric MRI changes persist beyond recovery in concussed adolescent hockey players 2) Neurology Today® paper on the increase in gabapentinoid prescriptionThis podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the November 21, 2017 issue of Neurology. In the first segment, Dr. Ted Burns talks with Dr. Kathryn Manning and Dr. Ravi Menon about their paper regarding the effects of concussion on adolescent hockey players. In the second part of the podcast, Dr. Burns focuses his interview with Dr. Christopher Goodman about a recent Neurology Today article discussing the increase in gabapentinoid prescriptions. Disclosures can be found at Neurology.org.DISCLOSURES: Dr. Burns is the deputy section editor of the Neurology® podcast; has served on scientific advisory boards for Argenx, UCB, and CSL Behring; has received travel funding/speaker honoraria from Argenx and Alexion; and has received support for consulting activities from UCB Pharma and CSL Behring.Dr. Manning reports no disclosures.Dr. Menon has served on the scientific advisory board of International Initiative for Traumatic Brain Injury Research (NIH/EU/CIHR); has served on the editorial boards of NeuroImage, Journal of Neurophysiology, Scientific Reports, and Tomography; has received research support from Siemens Healthineers, Canadian Institutes of Health Research, Natural Sciences and Engineering Research Council of Canada, Canada First Research Excellence Fund, and Brain Canada Foundation; and has received royalty payments from Siemens Healthcare for US Patent 8,193,812.Dr. Goodman reports no disclosures.

Show description/summary:1) Infliximab for the treatment of central nervous system sarcoidosis: A multi-institutional series2) What’s Trending: Sonic traumatic brain injuryThis podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the November 14, 2017 issue of Neurology. In the first segment, Dr. Stacey Clardy talks with Dr. Siddharama Pawate and Dr. Jeff Gelfand about their paper on infliximab for treatment of central nervous system sarcoidosis. In the second part of the podcast, Dr. Alex Menze focuses his interview with Dr. Jeffrey Kim on the recent speculation around sonic traumatic brain injury.DISCLOSURES: Dr. Gelfand has served on scientific advisory boards for Genentech; has received compensation for consulting with Genentech; has received research support from Quest Diagnostics, Genentech, MedDay, and NIH National Center for Advancing Translational Sciences (KL2TR000143); and has received compensation for serving as expert witness in medical-legal consulting. Dr. Pawate has served on scientific advisory board for Biogen, and has received research support from Biogen.Dr. Clardy has received research support from Western Institute for Biomedical Research (WIBR).All other participants report no disclosures.

Show description/summary:1) This variant alters protein function, but is it pathogenic? (Neurology® Genetics)2) What’s Trending: PFO UpdatesThis podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the November 7, 2017 issue of Neurology. In the first segment, Dr. Michelle Mauermann talks with Dr. Massimo Pandolfo about his recent Neurology® Genetics editorial, entitled “This variant alters protein function, but is it pathogenic?”. In the second part of the podcast, Dr. Nicole Chiota focuses her interview with Dr. Steven Messe on recent PFO/stroke updates. Disclosures can be found at Neurology.org.DISCLOSURES: Dr. Mauermann serves on the editorial board of Mayo Clinic Proceedings; receives publishing royalties from Oxford, and has received research support from Ionis Pharmaceuticals, Inc. and Alnylam Pharmaceuticals.Dr. Pandolfo has served on the scientific advisory boards of Apopharma and Voyager Therapeutics; has served on the editorial boards of Acta Neurologica Belgica, Orphanet Journal of Rare Diseases, and Neurology Genetics; is co-holder of a patent for Direct molecular diagnosis of Friedreich’s ataxia; has been a consultant for Biomarin and UCB; has received research support from Biomarin, Fonds National de la Recherche Scientifique (Belgium), Offrez-moi-la-lune, Friedreich's Ataxia Research Alliance, and Association Belge contre les Maladies neuro-Musculaires, and receives royalty payments from Athena Diagnositcs for a Friedreich's ataxia diagnostic test.Dr. Chiota reports no disclosures.Dr. Messe has served on the scientific advisory board of the Yale University Cardiovascular Research Group; has received travel funding from the American Academy of Neurology; has received publishing royalties from Up To Date; has been a consultant for Claret Medical; and has received research support from WL Gore, Glaxo Smith Kline, Bayer, Mallinkrodt, and NIH.

This month’s Delayed Recall episode features Dr. Stacey Clardy’s Lesson of the Week interviews on the topic of immunotherapy, which originally aired in July 2017. In the first interview, Dr. Clardy speaks with Dr. Dennis Bourdette about new immunotherapies in neurology. This interview first appeared in the July 4 episode. In the interview from July 11, Dr. Clardy continues the discussion about new immunotherapies with Dr. Jeffrey Cohen. The third interview, from the July 18 episode, features Dr. Clardy speaking with Dr. Emmanuelle Waubant about immunotherapy as it applies to multiple sclerosis patients. To conclude this episode, we offer Dr. Clardy’s interview with Dr. Anne Cross, in which they talk about immunosuppressants in Neurology; this interview was part of the July 25 episode.

Show description/summary:1) Change in multimodal MRI markers predicts dementia risk in cerebral small vessel disease2) What’s Trending: dabigatran reversal in patients with uncontrolled bleeding This podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the October 31, 2017, issue of Neurology. In the first segment, Dr. Matthew Elliot talks with Dr. Hugh Markus about his paper multimodal MRI markers and dementia risk in cerebral small vessel disease. In the second part of the podcast, Dr. Bryan Eckerle focuses his interview with Dr. Charles Pollack on dabigatran reversal in patients with uncontrolled bleeding or receiving surgery. DISCLOSURES: Dr. Markus serves as section editor of International Journal of Stroke; serves on the editorial board for Clinical Neurology and Neurosurgery, and BMC Medicine; serves as Associate Editor for Fronteirs in Neurology; receives publishing royalties from Stroke Medicine (OUP 2016); has consulted and led a teaching session for Astra Zeneca; and has received research support from MRC, NIHR, Stroke Association, EU, Wellcome Trust, The British Heart Foundation, and Alzheimer Research UK. Dr. Eckerle and Dr. Elliot report no disclosures.Dr. Pollack has received research support from Boehringer Ingelheim, Daiichi Sankyo, CSL Behring, Janssen Pharma, AstraZeneca, and Portola; and has served as scientific consultant for Boehringer Ingelheim, BMS/Pfizer, Janssen Pharma, AstraZeneca, and Portola.

Show description/summary:1) Persistent focal enhancement of the cisternal segment of oculomotor nerve in ophthalmoplegic migraine (Neurology® Clinical Practice)2) What’s Trending: Tenecteplase for acute ischemic strokeThis podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the October 24, 2017 issue of Neurology. In the first segment, Dr. Heather Harle talks with Dr. Ihtesham Qureshi about his Neurology® Clinical Practice paper on ophthalmoplegic migraine. In the second part of the podcast, Dr. Justin Sattin focuses his interview with Dr. Nicola Logalio on using tenecteplase for acute ischemic stroke. Disclosures can be found at Neurology.org.DISCLOSURES: All participants report no disclosures.

Show description/summary:1) Qualitative study of burnout, career satisfaction, and well-being among US neurologists in 20162) What’s Trending: gene editing in human embryosThis podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the October 17, 2017, issue of Neurology. In the first segment, Dr. Pearce Korb talks with Dr. Janis Miyasaki about her paper on burnout, career satisfaction and well-being among US neurologists. In the second part of the podcast, Dr. Jason Crowell focuses his interview with Dr. Shoukhrat Mitalipov on gene editing in human embryos for correction of a pathogenic mutation.DISCLOSURES: Dr. Miyasaki has received honoraria from Davis Phinny Foundation, Sunovion, and NINDS; receives publishing royalties from “Up to Date: Psychogenic Movement Disorders;” has consulted for Cynapsus and GE; has served on a scientific advisory board for Parkinson Society Canada; and has received research support from Allergan, PCORI, and Parkinson Alberta.Dr. Mitalipov holds patents for Primate Totipotent and Pluripotent Stem Cells Produced by Somatic Cell Nuclear Transfer (U.S. patent No. 7,972,849), Human Pluripotent Stem Cells Produced by Somatic Cell Nuclear Transfer (U.S. Patent No. 9,546,383), and Methods for Mitochondrial DNA Replacement in Oocytes (U.S. Patent No. 9434921); has patents pending for Metabolic rescue in pluripotent cells from subjects with mitochondrial DNA disease (Application Number: 62192358), Generation of human oocytes by polar body transfer” (Application 62/419,638), and Mitochondrial Replacement in Human Oocytes Carrying Pathogenic Mitochondrial DNA Mutations (Application 62427546); has consulted for Flagship VentureLabs; and has received research support from NIH/NIA, Burroughs Wellcome Fund, and Foundation Leducq.Dr. Korb and Dr. Crowell report no disclosures.

Show description/summary:1) Quality improvement in neurology: Stroke and stroke rehabilitation quality measurement set update2) Neurology Today® paper on Parkinson disease and autoimmunityIn the first segment, Dr. Dan Ackerman talks with Dr. Gene Latorre about his paper on the updated quality measurement set for stroke and stroke rehabilitation. In the second part of the podcast, Dr. Alberto Espay focuses his interview with Dr. David Sulzer on Parkinson disease and autoimmunity. Disclosures can be found at Neurology.org.DISCLOSURES: Dr. Espay serves as Associate Editor for the Journal of Clinical Movement Disorders; serves as an editorial board member of Parkinsonism and Related Disorders and The European Neurological Journal; serves on the scientific advisory board for Solvay Pharmaceuticals, Inc. (now Abbvie), Chelsea Therapeutics International, Ltd., Teva Pharmaceutical Industries Ltd., Impax, Merz Pharmaceuticals, Inc., Pfizer Inc, Solstice Neurosciences, Eli Lilly and Company, ACADIA Pharmaceuticals, Inc. and USWorldMeds; is a consultant for Chelsea Therapeutics International, Ltd., Solvay Pharmaceuticals, Inc. (now Abbvie), ACADIA Pharmaceuticals, Inc., Cynapsus and Lundbeck, Inc; receives royalties for publications of books from Lippincott, Williams & Wilkins and Cambridge University Press; serves on the speakers' bureau of UCB, Teva Pharmaceutical Industries Ltd., American Academy of Neurology and Movement Disorders Society; receives research support from the CleveMed/Great Lake Neurotechnilogies, Michael J. Fox Foundation and the NIH.All other participants report no disclosures.

Show description/summary:1) Functional impairments for outcomes in a randomized trial of of unruptured brain AVMs2) What’s Trending: Hurricane Harvey and patient care in TexasThis podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the October 3, 2017, issue of Neurology. In the first segment, Dr. Andrew Southerland talks with Dr. JP Mohr about his paper on functional impairment outcome measurements in a randomized trial of unruptured brain arteriovenous malformations. In the second part of the podcast, Dr. Jason Crowell focuses his interview with Dr. Aziz Shaibani on Hurricane Harvey and its effect on patient care in Texas. Disclosures can be found at Neurology.org.DISCLOSURES: Dr. Southerland serves as Podcast Editor for Neurology; receives research support from the American Heart Association-American Stroke Association National Clinical Research Program, American Academy of Neurology, American Board of Psychiatry and Neurology, Health Resources Services Administration and the NIH; has a provisional patent application titled: “Method, system and computer readable medium for improving treatment times for rapid evaluation of acute stroke via mobile telemedicine;” and gave legal expert review.Dr. Mohr serves as Associate Editor for History of Stroke and Cerebrovascular Disease; has consulted for Schering-Plough; has given expert testimony on unruptured brain AVMs; and has received research support from NINDS associated with the ARUBA trial. Dr. Crowell reports no disclosures.Dr. Shaibani is President-Elect for the Texas Neurology Society.